Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
Nature Biotechnology, Journal Year: 2025, Volume and Issue: 43(4), P. 516 - 533
Published: April 1, 2025
Language: Английский
Citations
1
Molecules and Cells, Journal Year: 2025, Volume and Issue: unknown, P. 100177 - 100177
Published: Jan. 1, 2025
The role of γδ T cells in antitumor responses has gained significant attention due to their unique major histocompatibility complex (MHC)-independent killing mechanisms, which distinguish them from conventional αβ cells. Notably, tumor-infiltrating lymphocytes (TILs) have been identified as favorable prognostic markers various cancers. However, TIL subsets, including Vδ1, Vδ2, and Vδ3, exhibit distinct implications phenotypes one another within the tumor microenvironment (TME). Although underlying mechanisms remain unclear, recent studies suggest that these subset-specific differences may arise divergent activation pathways. Vδ1 TILs appear be mainly activated by T-cell receptor (TCR) signaling, whereas Vδ2 seem rely on alternative pathways, such natural killer (NK) receptor-mediated activation. In addition phenotypic studies, cell-based immunotherapies are being actively developed using innovative approaches engineered cells, cell engager molecules, TCR-based therapies. Despite advancements, challenges functional heterogeneity limited vivo persistence unresolved. Overcoming obstacles could position therapies a transformative platform for cancer immunotherapy. This review explores findings markers, characteristics human TME, advancements immunotherapies, offering valuable insights development novel therapeutic strategies.
Language: Английский
Citations
0
International review of cell and molecular biology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
0
Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1063 - 1063
Published: March 21, 2025
Gamma delta (γδ) T cells are a unique subset of lymphocytes with distinctive features that make them highly promising candidates for cancer therapy. Their MHC-independent recognition tumor antigens, ability to mediate direct cytotoxicity, and role in modulating the microenvironment position as versatile agents immunotherapy. This review integrates synthesizes existing data on γδ cells, an emphasis development optimization vitro expansion protocols. Critical aspects detailed such activation strategies, co-culture systems, cytokine use, other parameters ensure robust cell proliferation functionality, which may be valuable those developing or optimizing clinical practices. Finally, we discuss current advancements research, experience, highlight areas needing further exploration. Considering these data, hypothesize propose potential new applications engineering enhanced resistance immune checkpoint pathways localized delivery within microenvironment, could broaden their therapeutic impact treatment beyond.
Language: Английский
Citations
0
Biomarker Research, Journal Year: 2025, Volume and Issue: 13(1)
Published: March 28, 2025
Language: Английский
Citations
0
Nature reviews. Immunology, Journal Year: 2024, Volume and Issue: 24(7), P. 458 - 458
Published: June 11, 2024
Language: Английский
Citations
0
Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 103 - 153
Published: Oct. 25, 2024
Language: Английский
Citations
0
Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 35 - 59
Published: Oct. 25, 2024
Language: Английский
Citations
0
Immuno-Oncology Technology, Journal Year: 2024, Volume and Issue: 24, P. 100740 - 100740
Published: Nov. 5, 2024
γδ T cells represent an 'unconventional' class of CD3+ lymphocytes with unique phenotypical and functional attributes that distinguishes them from their αβ T-cell receptor-expressing counterparts. Studies investigating the roles in cancer have shown these are indispensable for effective tumor control presence within may be prognostic significance. Currently, there is significant interest harnessing treatment, research efforts focused on development T-cell-based strategies efficacious against cancer. Several therapeutic approaches using been described, premised expansion or chimeric antigen receptor therapy. The potential broad, unbiased 'off-the-shelf' applicability drives ongoing future methodologies by which can exploited use. In this review, we will briefly outline characteristics describe how work promote proper functioning cancer-immunity cycle. Additionally, introduce less commonly described potentially more than other types Our discussion expand upon presently known applications even highlight versatility immune subset as therapeutics. treatment emerging strategy should considered cancelling
Language: Английский
Citations
0
Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
Citations
0